Abstract |
Previous studies have demonstrated that the -141C Ins/Del and TaqI A polymorphisms in the DRD2 gene affect the density of the dopamine D2 receptor. The present study examines the correlation between these two polymorphisms and the therapeutic response to chlorpromazine, a typical antipsychotic drug, in 135 inpatients with schizophrenia. Clinical symptoms were evaluated using the Brief Psychiatry Rating Scale (BPRS) before and after 8 weeks of treatment with 300-600 mg/day of chlorpromazine. Our results show that genotyping -141C Ins/Del may help to predict the efficacy of chlorpromazine treatment (P=0.01) due to the fact that patients with no Del allele showed greater improvement than those with Del allele on the overall BPRS (P=0.03), and that, therefore, the potential for therapy in patients with schizophrenia is related to the -141C Ins/Del polymorphism in the DRD2 gene. However, no such relationship was found for the TaqI A polymorphism.
|
Authors | Shengnan Wu, Qinghe Xing, Rui Gao, Xingwang Li, Niufan Gu, Guoyin Feng, Lin He |
Journal | Neuroscience letters
(Neurosci Lett)
Vol. 376
Issue 1
Pg. 1-4
(Mar 07 2005)
ISSN: 0304-3940 [Print] Ireland |
PMID | 15694263
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antipsychotic Agents
- DRD4 protein, human
- RNA, Messenger
- Receptors, Dopamine D2
- Receptors, Dopamine D4
- Taq Polymerase
- Chlorpromazine
|
Topics |
- Adult
- Antipsychotic Agents
(therapeutic use)
- China
(epidemiology)
- Chlorpromazine
(therapeutic use)
- Female
- Gene Deletion
- Genetic Predisposition to Disease
- Genotype
- Humans
- Male
- Polymorphism, Genetic
- Psychiatric Status Rating Scales
- RNA, Messenger
(biosynthesis)
- Receptors, Dopamine D2
(genetics)
- Receptors, Dopamine D4
- Reverse Transcriptase Polymerase Chain Reaction
(methods)
- Schizophrenia
(drug therapy, genetics)
- Taq Polymerase
|